Value of Central Venous to Arterial CO(2) Difference after Early Goal-directed Therapy in Septic Shock Patients

脓毒性休克患者早期目标导向治疗后中心静脉与动脉二氧化碳差值的价值

阅读:1

Abstract

BACKGROUND AND AIMS: Venous to arterial difference of carbon dioxide (Pv-aCO(2)) tracks tissue blood flow. We aimed to evaluate if Pv-aCO(2) measured from a superior central vein sample is a prognostic index (ICU length of stay, SOFA score, 28th mortality rate) just after early goal-directed therapy (EGDT)comparing its ICU admission values between patients with normal and abnormal (>6 mm Hg) Pv-aCO(2). As secondary objectives, we evaluated the relationship of Pv-aCO(2) with other variables of perfusion during the 24 hours that followed EGDT. MATERIALS AND METHODS: Prospective observational study conducted in an academic ICU adult septic shock patients after a 6-hour complete EGTD. Hemodynamic measurements, arterial/central venous blood gases, and arterial lactate were obtained on ICU admission and after 6, 18 and 24 hours. RESULTS: Sixty patients were included. Admission Pv-aCO(2) values showed no prognostic value. Admission Pv-aCO(2) (ROC curve 0.527 [CI 95% 0.394 to 0.658]) values showed low specificity and sensitivity as predictors of mortality. There was a difference observed in the mean Pv-aCO(2) between nonsurvivors (NS) and survivors (S) after 6 hours. Central venous oxygen saturation (ScvO(2)) and Pv-aCO(2) showed significant correlation (R2 = -0.41, P < 0.0001). Patients with normal ScvO(2) (>70%) and abnormal Pv-aCO(2) (>6 mm Hg) showed higher SOFA scores. Normal Pv-aCO(2) group cleared their lactate levels in comparison to the abnormal Pv-aCO(2) group. CONCLUSION: In septic shock, admission Pv-aCO(2) after EGDT is not related to worse outcomes. An abnormal Pv-aCO(2) along with a normal ScvO(2) is related to organ dysfunction. HOW TO CITE THIS ARTICLE: Araujo DT, Felice VB, Meregalli AF, Friedman G. Value of Central Venous to Arterial CO(2) Difference after Early Goal-directed Therapy in Septic Shock Patients. Indian J Crit Care Med 2019;23(10):449-453.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。